catalyst · primary record
Nipocalimab + Placebo
Phase readout · 2026-12-15 · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
| Company | Janssen Research & Development, LLC |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P2/P3 primary completion · NCT05327114 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:56:19.055Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Janssen Research & Development, LLC:Nipocalimab + Placebo:2026-12-15:P2/P3 primary completion · NCT05327114
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.